Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ACLARUBICIN for T-cell type acute leukaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 10 adverse event reports in the FDA FAERS database where ACLARUBICIN was used for T-cell type acute leukaemia.

Most Reported Side Effects for ACLARUBICIN

Side Effect Reports % Deaths Hosp.
Myelosuppression 80 25.5% 3 20
Bone marrow failure 73 23.3% 14 7
Off label use 38 12.1% 6 4
Nausea 35 11.2% 1 2
Infection 26 8.3% 2 1
Acute myeloid leukaemia 24 7.6% 11 8
Product use in unapproved indication 22 7.0% 1 1
Platelet count decreased 21 6.7% 5 9
Febrile neutropenia 19 6.1% 8 5
Pneumonia 19 6.1% 11 5
Thrombocytopenia 18 5.7% 4 4
Anaemia 17 5.4% 3 3
Alopecia 16 5.1% 0 0
Diarrhoea 16 5.1% 2 2
Drug-induced liver injury 16 5.1% 2 0

Other Indications for ACLARUBICIN

Acute myeloid leukaemia (168) Myelodysplastic syndrome (18) Acute myeloid leukaemia refractory (15) Chemotherapy (13) Acute leukaemia (11) Acute myeloid leukaemia recurrent (11) Product used for unknown indication (9) Myelodysplastic syndrome with excess blasts (8) Acute promyelocytic leukaemia (7) B-cell lymphoma (6)

Other Drugs Used for T-cell type acute leukaemia

VINCRISTINE (763) METHOTREXATE (739) CYTARABINE (520) DEXAMETHASONE (452) CYCLOPHOSPHAMIDE (436) DAUNORUBICIN (367) DOXORUBICIN (306) PEGASPARGASE (297) ASPARAGINASE (282) MERCAPTOPURINE (251)

Related Pages

ACLARUBICIN Full Profile All T-cell type acute leukaemia Drugs ACLARUBICIN Demographics ACLARUBICIN Timeline